AbbVie Analyst Price Targets

AbbVie Inc

ABBVNYSE

Trade with Public

$282.68

-2.74-0.96%

Ult. Agg.: Oct 19, 7:47 PM

$282.60

-2.82-0.99%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

Dividendo: La data di stacco del dividendo è stata 4 giorni fa

Utili: I risultati di Q3 2026 tra 11 giorni da adesso in ven ott 30th, prima dell'apertura del mercato

AbbVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for AbbVie (ABBV).

Price Target Range — 8 Quarters

Analyst Consensus — 25 Analysts

21Buy

4Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$271Upside to Avg. PT-4.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	RBC Capital	Trung Huynh	Maintained	Outperform	$280
Oct 9, 2026	UBS	Michael Yee	PT Raise	Neutral	$260→$275
Oct 9, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$288
Oct 8, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$285→$300
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$285→$290
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$296→$310
Oct 6, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$280→$320
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$300→$315
Aug 20, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$298→$303
Aug 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$295→$300
Aug 13, 2026	Wolfe Research	Alexandria Hammond	Upgrade	Peer Perform→Outperform	$300
Aug 11, 2026	BNP Paribas	Navann Ty	PT Raise	Neutral	$218→$247
Aug 10, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$246→$260
Aug 6, 2026	Berenberg	Luisa Hector	Maintained	Buy	$275
Aug 5, 2026	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 4, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$261→$288
Aug 3, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$278→$296
Aug 3, 2026	Canaccord Genuity	Gary Nachman	PT Raise	Buy	$282→$290
Aug 3, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$265→$285
Jul 31, 2026	TD Cowen	Steve Scala	Maintained	Buy	$280

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

RBC Capital analyst Trung Huynh reiterates AbbVie (NYSE:ABBV) with a Outperform and maintains $280 price target.

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

Benzinga Newsdesk

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $288 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.

Benzinga Newsdesk

AbbVie Inc

AbbVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PRO
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AbbVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PRO
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

People Also Watch

People Also Watch

AbbVie Inc

AbbVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PROCNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PROUBS Maintains Neutral on AbbVie, Raises Price Target to $275

PROGuggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PROJP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PROCantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AbbVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PROCNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PROUBS Maintains Neutral on AbbVie, Raises Price Target to $275

PROGuggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PROJP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PROCantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

People Also Watch

People Also Watch

PRO
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PRO
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

PRO
RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

PRO
CNBC Halftime Report Final Trades: AbbVie, DocuSign, Netflix

PRO
UBS Maintains Neutral on AbbVie, Raises Price Target to $275

PRO
Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

PRO
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

PRO
Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290